Nymox Pharmaceutical Corporation

NYMXF

BSP733981026

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 09:50:52 30/04/2024 pm IST			5-day change	1st Jan Change
0.3498 ^USD	+7.65%		+16.60%	-40.71%

2023	Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH	CI

Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from S&P Global BMI Index

September 20, 2021 at 09:30 am IST

Latest news about Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH	25/23/25	CI
Nymox Pharmaceutical Corporation announced that it has received $2 million in funding	29/23/29	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Nymox Pharmaceutical Corporation announced that it expects to receive $2 million in funding	02/23/02	CI
Nymox Pharmaceutical Corporation Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results	25/23/25	CI
Nymox Pharmaceutical Corporation Appoints Patrick Doody as Vice President, General Counsel and Member of Board of Directors	12/23/12	CI
Fed Outlook Weighs on Exchange-Traded Funds, Equity Futures Premarket Thursday	06/23/06	MT
Nymox Pharmaceutical Receives Delisting Notice From Nasdaq	06/23/06	MT
Nymox Pharmaceutical Corporation(OTCPK:NYMX.F) dropped from NASDAQ Composite Index	06/23/06	CI
Nymox Pharmaceutical Corporation Announces Removal of Board of Directors	28/23/28	CI
Nymox Pharmaceutical Corporation Announces Termination of Christopher R. Riley as Chief Financial Officer	28/23/28	CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell Microcap Index	23/23/23	CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell Microcap Growth Index	23/23/23	CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 3000E Index	23/23/23	CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 3000E Growth Index	23/23/23	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	02/23/02	CI
Nymox Pharmaceutical Corporation Auditor Raises 'Going Concern' Doubt	02/23/02	CI
Nymox Pharmaceutical Names Christopher Riley as CFO	21/23/21	MT
Nymox Pharmaceutical Corporation Announces Appointment of Christopher R. Riley as Chief Financial Officer	21/23/21	CI
Nymox Pharmaceutical Gets Nasdaq Extension to Comply With Listing Requirements; Shares Rise	15/23/15	MT
Nymox Pharmaceutical Corporation Announces New Marketing Submission for Nymozarfex for BPH	05/22/05	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	17/22/17	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/22/15	CI

Chart Nymox Pharmaceutical Corporation

Duration

Period

More charts

Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company focused on developing its drug candidate, NX-1207, for treating benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The Companyâs activities and resources have been directed primarily at developing certain pharmaceutical technologies. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (BPH) and for low grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a personâs level of exposure to tobacco products, including secondhand smoke. The Company started two pivotal double-blind placebo-controlled Phase III trials for NX-1207, NX02-0017 and NX02-0018, conducted at investigational sites across the United States with a total enrollment of approximately 1,000 patients.

Sector

Biotechnology & Medical Research

Calendar

15/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NYMOX PHARMACEUTICAL CORPORATION	-40.71%	30.34M
IQVIA HOLDINGS INC.	+0.47%	42.86B
MODERNA, INC.	+12.23%	42.74B
LONZA GROUP AG	+44.30%	41.36B
CELLTRION, INC.	-6.20%	27.68B
ICON PUBLIC LIMITED COMPANY	+5.66%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.80%	18.63B
MEDPACE HOLDINGS, INC.	+27.96%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.61%	11.92B
UNITED THERAPEUTICS CORPORATION	+7.00%	11.21B